Bedrocan - THC 22% | CBD <1.0%
Product Description
Bedrocan
-
Country/Region:Netherlands
-
On CPHI since:2018
-
Certificates:2
-
Employees:50 - 99
Company types
Primary activities
Categories
Specifications
Bedrocan
-
Country/Region:Netherlands
-
On CPHI since:2018
-
Certificates:2
-
Employees:50 - 99
Company types
Primary activities
More Products from Bedrocan (2)
-
Product Bedrolina®- THC 14% | CBD <1.0%
Introduced in 2024, Bedrolina® Bedrolina® is the brand name for the indica cultivar Cannabis sativa L. ‘Janna’, and it is the most recent product launched in our portfolio. Cannabis sativa L. ‘Janna’ was developed to supply a product with higher CBD content that facilitat... -
Product Bediol - THC 6.3% | CBD 8%
Introduced in 2007, Bediol® is the brand name for the cultivar Cannabis sativa L. ‘Elida’. Cannabis sativa L. ‘Elida’ is one of the first cannabis cultivars developed specifically to have a higher CBD content. The effects of CBD are distinctly different from THC. Bediol® has a balanced...
Bedrocan resources (2)
-
News Bedrocan develops new practice for cannabis cultivation
Bedrocan has developed a new practice for medicinal cannabis cultivation. The practice is already in use at Bedrocan’s facilities and is called GMCCP: Good Medicinal Cannabis Cultivation Practice. According to Bedrocan, GACP is not sufficient for cannabis intended for medicinal use, hence the need for a special practice for the cultivation of medicinal cannabis.
-
Industry Webinar Cannabis-based medicine and chronic pain
Monique van Velzen is research manager, assistant professor and supervisor of medical researchers at the Anesthesiology department of the LUMC in Leiden, Netherlands. Her research focuses on understanding patients with (chronic) pain better and studying the most optimal form of pain relief. Since 2017, Monique has been supervising research into medicinal cannabis for specific types of pain. For more information about the webinars, visit www.bedrocan.com/series

